Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial (Q43943002)

28 November 2017

Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial (English)

1 reference

28 November 2017

0 references

0 references

4

1 reference

28 November 2017

Jim J Egan

1

1 reference

28 November 2017

Kevin B Carroll

series ordinal

2

1 reference

28 November 2017

Nizar Yonan

series ordinal

3

1 reference

28 November 2017

Adam Crisp

series ordinal

5

1 reference

28 November 2017

1 April 2002

1 reference

The Journal of Heart and Lung Transplantation

28 November 2017

1 reference

28 November 2017

21

1 reference

28 November 2017

4

1 reference

28 November 2017

460-466

1 reference

Cytomegalovirus prophylaxis in solid organ transplant recipients

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

Increased Pulmonary Superinfections in Cardiac-Transplant Patients Undergoing Primary Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

Impact of cytomegalovirus infection on organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

The cost impact of cytomegalovirus disease in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900399-0

7 January 2021

10.1016/S1053-2498(01)00399-0

Identifiers

DOI

1 reference

28 November 2017

1 reference